Ocugen has been granted a patent for a method of treating tissue defects using a double-structured tissue implant. The implant consists of a primary scaffold and a secondary scaffold made of soluble collagen and a non-ionic surfactant. The method involves preparing the implant, preparing the tissue defect, precutting the implant, coating the defect with a tissue adhesive, implanting the double-structured tissue implant, and covering it with another tissue adhesive. GlobalData’s report on Ocugen gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Ocugen, customized implants was a key innovation area identified from patents. Ocugen's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Method for treating tissue defects using a double-structured tissue implant
A recently granted patent (Publication Number: US11648102B2) describes a method for treating tissue defects using a double-structured tissue implant. The method involves several steps, including preparing the implant, preparing the tissue defect for implantation, precutting the implant, coating the defect with a tissue adhesive, implanting the double-structured tissue implant into the defect, and covering the implant with a second tissue adhesive.
The primary scaffold of the implant defines the top and bottom surfaces of the implant. The collagen used in the implant is lyophilized at a specific temperature range and dehydrothermally treated for a specific duration. The pores in the implant have a diameter of approximately 300±100 pm, and the sizes and diameters of the pores on both surfaces of the implant are substantially the same. These pores are vertically oriented.
The secondary scaffold of the implant is made of Type I collagen. A surfactant, specifically a derivatized polyethylene glycol, is used in the implant. Additionally, the implant may contain a morphogenetic growth factor, a modulator, or a pharmaceutical agent, among other substances. Examples of these substances include growth factors, growth hormones, mediators, enzymes promoting cell incorporation, enzymes promoting cell proliferation, pharmaceutically acceptable excipients, additives, buffers, transforming growth factors, insulin-like growth factor 1, platelet-derived growth factors, repulsive guidance molecules, and bone morphogenetic proteins (BMPs).
This patented method offers a comprehensive approach to treating tissue defects by utilizing a double-structured tissue implant. The precise preparation and characteristics of the implant, such as the lyophilization and dehydrothermal treatment of collagen, the specific pore size and orientation, and the use of a secondary scaffold made of Type I collagen, contribute to its effectiveness. The inclusion of various substances like growth factors and pharmaceutical agents further enhances the potential therapeutic benefits of the implant. This patent provides valuable insights and techniques for clinicians and researchers working in the field of tissue defect treatment.
To know more about GlobalData’s detailed insights on Ocugen, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
